InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Zeskind Benjamin J., Chairman & CEO. Officer active across 1 companies, notably Immuneering Corp. Cumulatively, 7 filings have been recorded. Total volume traded: €102k. The latest transaction was disclosed on 12 April 2022 — Levée d'options. Regulator: SEC (Form 4). All data is openly available.
Declarations7 total
€5,5612,000 shares@ €2.78030.0017% mcap4.9% of flow
Class A Common Stock
SEC:0001415889-22-004065:0·
€21,8143,000 shares@ €7.27130.0065% mcap19.2% of flow
Class A Common Stock
SEC:0001415889-22-003324:0·
Ideal exit: 18 Dec 2022 (T+270)
€5,3842,000 shares@ €2.69210.0016% mcap4.7% of flow
Class A Common Stock
SEC:0001415889-22-002061:0·
€40,3252,083 shares@ €19.35920.012% mcap100.0% of flow
Class A Common Stock
SEC:0001415889-21-004382·
Ideal exit: 10 Jun 2022 (T+270)
€40,3252,083 shares@ €19.35920.012% mcap35.6% of flow
Class A Common Stock
SEC:0001415889-21-004382:0·
Ideal exit: 10 Jun 2022 (T+270)
49,099 shares
Class A Common Stock
SEC:0001104659-21-099741·
49,099 shares
Class A Common Stock
SEC:0001104659-21-099741:0·
7 of 7 declarations
About Zeskind Benjamin J.
Benjamin J. Zeskind is the President and CEO of Immuneering Corp. He leads the company with a strategic vision focused on innovation and growth. Zeskind brings significant expertise in business management and product development, thus contributing to Immuneering's mission to provide advanced therapeutic solutions. His leadership is essential for navigating the dynamic biotechnology market.
